Introducing Incubate Policy Lab, a dynamic platform dedicated to delivering regular updates through white-papers and research. Drawing from a deep understanding of the early-stage life science ecosystem, our lab explores vital insights to foster informed investments that catalyze innovation.
The Cost of Paying Other Countries’ Drug Prices
Foreign reference pricing models like the Most Favored Nation (MFN) may sound appealing but would ultimately harm Americans by limiting access to care and weakening the U.S. biotech industry. With rigid price controls abroad and growing global competition—especially from China—such policies risk undermining U.S. leadership in drug development and driving investment elsewhere.
Small Molecules, Big Impact
Imagine your loved one is diagnosed with a cancer that, up until a few years ago, was only treatable with an hours-long infusion that had to be repeated in a hospital every couple of weeks. Now imagine that same cancer can be treated just as effectively with a pill your family member can take orally, at home, on a set schedule.
Kirsten Axelsen
Senior Policy Lab Advisor
Kirsten works with leaders in life sciences companies to navigate policy, competition, reimbursement and public perception for successful product launch, growth and for profitability. She has diverse experience developing and executing strategy at all stages of the biopharmaceutical lifecycle and in all major markets.
IP Protections for Medicines
Intellectual property protections in the U.S. incentivize investment in drug development, leading to life-saving innovations, while also facilitating the entry of cost-saving generic medicines after exclusivity periods expire, though debates persist over the balance between incentivizing innovation and promoting access to affordable medications.